Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

61. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial (Abstract)

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial Resistance to first-generation or second-generation EGFR tyrosine kinase inhibitor (TKI) monotherapy develops in almost half of patients with EGFR-positive non-small-cell lung cancer (NSCLC) after 1 year of treatment. The JO25567 phase 2 trial comparing erlotinib plus bevacizumab (...) with activating EGFR genomic aberrations from 69 centres across Japan. Eligible patients were at least 20 years old, and had an Eastern Cooperative Oncology Group performance status of 2 or lower, no previous chemotherapy for advanced disease, and one or more measurable lesions based on Response Evaluation Criteria in Solid Tumours (1.1). Patients were randomly assigned (1:1) to receive oral erlotinib 150 mg per day plus intravenous bevacizumab 15 mg/kg once every 21 days, or erlotinib 150 mg per day

2019 EvidenceUpdates

62. Multidisciplinary home-based rehabilitation in inoperable lung cancer: a randomised controlled trial (Abstract)

Multidisciplinary home-based rehabilitation in inoperable lung cancer: a randomised controlled trial Lung cancer is associated with poor health-related quality of life (HRQoL) and high symptom burden. This trial aimed to assess the efficacy of home-based rehabilitation versus usual care in inoperable lung cancer.A parallel-group, assessor-blinded, allocation-concealed, randomised controlled trial. Eligible participants were allocated (1:1) to usual care (UC) plus 8 weeks of aerobic (...) found for HRQoL (Functional Assessment of Cancer Therapy-Lung: 13.0 (3.9 to 22.1), p=0.005) and symptom severity (MD Anderson Symptom Inventory-Lung Cancer: -2.2 (-3.6 to -0.9), p=0.001).Home-based rehabilitation did not improve functional exercise capacity but there were improvements in patient-reported exploratory secondary outcomes measures observed at 6 months.Australian New Zealand Clinical Trials Registry (ACTRN12614001268639).© Author(s) (or their employer(s)) 2019. No commercial re-use. See

2019 EvidenceUpdates

63. Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer

Recommendations Recommendations 1.1 Atezolizumab plus bevacizumab, carboplatin and paclitaxel is recommended as an option for metastatic non-squamous non-small-cell lung cancer (NSCLC) in adults: who have not had treatment for their metastatic NSCLC before and whose PD-L1 tumour proportion score is between 0% and 49% or when targeted therapy for epidermal growth factor receptor (EGFR)-positive or anaplastic lymphoma kinase (ALK)-positive NSCLC has failed. It is recommended only if: atezolizumab (...) score between 0% and 49% and metastatic non-squamous EGFR- or ALK-positive NSCLC when targeted therapy is either not an option or has failed. Pembrolizumab monotherapy is the current treatment for untreated metastatic non-squamous Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 28NSCLC with a PD-L1 tumour

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

64. Paclitaxel (Pazenir) - metastatic breast cancer, non-small cell lung cancer

Paclitaxel (Pazenir) - metastatic breast cancer, non-small cell lung cancer Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/159292/2019 EMEA/H/C/004441 Pazenir (paclitaxel (...) ) An overview of Pazenir and why it is authorised in the EU What is Pazenir and what is it used for? Pazenir is used to treat the following cancers in adults: • metastatic breast cancer, when the first treatment has stopped working and standard treatment including an ‘anthracycline’ (another type of cancer medicine) is not suitable. ‘Metastatic’ means that the cancer has spread to other parts of the body; • non-small cell lung cancer, as a first treatment in combination with the cancer medicine carboplatin

2019 European Medicines Agency - EPARs

65. Brigatinib (Alunbrig) - for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)

in this indication has been considered by SMC using its decision-making framework for the assessment of ultra-orphan medicines. Nature of condition ALK-positive NSCLC is a rare form of lung cancer with ALK gene rearrangements occurring in approximately 5% of patients with NSCLC. ALK-positive disease is more common in younger patients, with adenocarcinoma histology who have never smoked. 2, 3 Until recently, crizotinib has been the standard first-line treatment of ALK-positive NSCLC and although it is effective (...) in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. The Lancet Oncology. 2016;17(12):1683-96. 10. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non- small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow- up. Annals of oncology : official journal of the European Society for Medical Oncology. 2018;29(Supplement_4):iv192-iv237. Epub 2018/10/05. 11. Scottish

2019 Scottish Medicines Consortium

66. Durvalumab (Imfinzi) - for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC)

considered under the ultra-orphan and end of life process durvalumab (Imfinzi®) is accepted for use within NHSScotland. Indication under review: as monotherapy for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 [programmed cell death ligand 1] on =1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy. Durvalumab, compared with placebo, improved progression-free survival and overall (...) and Clinician Engagement (PACE) meeting. Chairman Scottish Medicines Consortium www.scottishmedicines.org.uk 2 Indication As monotherapy for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 [programmed cell death ligand 1] on = 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy. 1 Dosing Information Durvalumab 10mg/kg intravenous (IV) infusion over 60 minutes every 2 weeks, until

2019 Scottish Medicines Consortium

67. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. (Abstract)

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a programmed death ligand 1 (PD-L1) tumour proportion score (TPS) of 50% or greater. We investigated overall survival after treatment (...) with pembrolizumab monotherapy in patients with a PD-L1 TPS of 1% or greater.This randomised, open-label, phase 3 study was done in 213 medical centres in 32 countries. Eligible patients were adults (≥18 years) with previously untreated locally advanced or metastatic non-small-cell lung cancer without a sensitising EGFR mutation or ALK translocation and with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, life expectancy 3 months or longer, and a PD-L1 TPS of 1% or greater

2019 Lancet Controlled trial quality: predicted high

68. Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation

authorisation indication indication Durvalumab (Imfinzi, AstraZeneca) is indicated 'as monotherapy for the treatment of locally advanced, unresectable non-small-cell lung cancer in adults whose tumours express PD-L1 on =1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation' . Dosage in Dosage in the the mark marketing eting authorisation authorisation 10 mg/kg administered as an intravenous infusion over 60 minutes every 2 weeks, until disease progression (...) There is an unmet need for treatment options in this disease area 3.1 Locally advanced unresectable non-small-cell lung cancer (NSCLC) is a highly heterogeneous disease with complex symptoms. Durvalumab is indicated for use in people whose tumours express PD-L1 on at least 1% of tumour cells and whose disease has not progressed after chemoradiation. At this stage, durvalumab has the potential to be curative. The patient expert explained that Durvalumab for treating locally advanced unresectable non-small-cell

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

69. Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning Full Text available with Trip Pro

) and the independent validation cohort (n=241; AUC 0.81, 95% CI 0.79-0.83), which showed significant improvement over previous studies using hand-crafted CT features or clinical characteristics (p<0.001). The deep learning score demonstrated significant differences in EGFR-mutant and EGFR-wild type tumours (p<0.001).Since CT is routinely used in lung cancer diagnosis, the deep learning model provides a non-invasive and easy-to-use method for EGFR mutation status prediction.Copyright ©ERS 2019. (...) Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning Epidermal growth factor receptor (EGFR) genotyping is critical for treatment guidelines such as the use of tyrosine kinase inhibitors in lung adenocarcinoma. Conventional identification of EGFR genotype requires biopsy and sequence testing which is invasive and may suffer from the difficulty of accessing tissue samples. Here, we propose a deep learning model to predict EGFR mutation status

2019 EvidenceUpdates

70. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database. Full Text available with Trip Pro

Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database. Data sets linking comprehensive genomic profiling (CGP) to clinical outcomes may accelerate precision medicine.To assess whether a database that combines EHR-derived clinical data with CGP can identify and extend associations in non-small cell lung cancer (NSCLC).Clinical data from EHRs were linked with CGP results for 28 998 patients (...) EHRs.Overall survival (OS), time receiving therapy, maximal therapy response (as documented by the treating physician in the EHR), and clinical benefit rate (fraction of patients with stable disease, partial response, or complete response) to therapy.Among 4064 patients with NSCLC (median age, 66.0 years; 51.9% female), 3183 (78.3%) had a history of smoking, 3153 (77.6%) had nonsquamous cancer, and 871 (21.4%) had an alteration in EGFR, ALK, or ROS1 (701 [17.2%] with EGFR, 128 [3.1%] with ALK, and 42 [1.0

2019 JAMA

71. Impact of thoracic radiation therapy after chemotherapy on survival in extensive-stage small cell lung cancer: A propensity score-matched analysis. Full Text available with Trip Pro

Impact of thoracic radiation therapy after chemotherapy on survival in extensive-stage small cell lung cancer: A propensity score-matched analysis. The role of thoracic radiation therapy (TRT) after chemotherapy (CHT) in extensive-stage small cell lung cancer (ES-SCLC) has not been well defined. We investigated whether intensity-modulated radiotherapy (IMRT) improves outcomes in ES-SCLC after CHT compared to CHT alone.A total of 292 patients who reached a complete response (CR), partial (...) patients reaching CR, PR or SD after CHT. A multicenter, randomized phase III clinical trial is needed to confirm these findings.© 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

2019 Thoracic cancer Controlled trial quality: uncertain

72. Alectinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

Gibbert ? Thomas Kaiser ? Inga Overesch ? Cornelia Rüdig ? Anke Schulz Keywords: alectinib, carcinoma – non-small-cell lung, benefit assessment, NCT02075840 Extract of dossier assessment A17-67 Version 1.0 Alectinib (non-small cell lung cancer) 28 March 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Table of contents Page List of tables iv List of abbreviations v 2 Benefit assessment 1 2.1 Executive summary of the benefit assessment 1 2.2 Research question 6 2.3 Information (...) -free survival QLQ-C30 Quality of Life Questionnaire-Core 30 QLQ-LC13 Questionnaire-Lung Cancer 13 RCT randomized controlled trial RECIST Response Evaluation Criteria in Solid Tumours SAE serious adverse event SGB Sozialgesetzbuch (Social Code Book) SPC Summary of Product Characteristics VAS visual analogue scale Extract of dossier assessment A17-67 Version 1.0 Alectinib (non-small cell lung cancer) 28 March 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - 1 - 2 Benefit assessment

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

73. Alectinib (non-small-cell lung cancer) - Addendum to Commission A17-67

Alectinib (non-small-cell lung cancer) - Addendum to Commission A17-67 1 Translation of addendum A18-30 Alectinib (nicht kleinzelliges Lungenkarzinom) – Addendum zum Auftrag A17-67 (Version 1.0; Status: 1 June 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 1 June 2018 1.0 Commission: A18-30 Version: Status: IQWiG Reports – Commission No. A18-30 (...) Alectinib (non-small cell lung cancer) – Addendum to Commission A17-67 1 Addendum A18-30 Version 1.0 Alectinib – Addendum to Commission A17-67 1 June 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Alectinib (non-small cell lung cancer) – Addendum to Commission A17-67 Commissioning agency: Federal Joint Committee Commission awarded on: 8 May 2018 Internal Commission No.: A18-30 Address

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

74. Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib

because it might control cancer at sites other than the lungs. The ALTA time on treatment and progression-free survival curves did not support that all people would remain on treatment after progressing. But the committee accepted that it was usual practice in the UK to continue treatment after radiological disease progression in some circumstances. Indirect comparison of brigatinib and ceritinib An indirect comparison is appropriate because there are no head-to-head trials An indirect comparison (...) a utility decrement of 0.15 from Chouaid et al. (2013), giving a utility estimate of Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 13 of 210.643 for progressed disease. The committee accepted the 0.15 utility decrement and the 0.643 utility value for those who have progressed on treatment, but did not consider 0.643

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

75. Bevacizumab (Zirabev) - cancers of the colon, rectum, breast, lung, kidney and cervix

Bevacizumab (Zirabev) - cancers of the colon, rectum, breast, lung, kidney and cervix 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/886373/2018 EMEA/H/C/004697 Zirabev (bevacizumab) An overview of Zirabev and why (...) it is authorised in the EU What is Zirabev and what is it used for? Zirabev is a cancer medicine that is used to treat adults with the following cancers: • cancer of the colon (large bowel) or the rectum (the last section of the bowel), when it has spread to other parts of the body; • breast cancer that has spread to other parts of the body; • a lung cancer called non-small cell lung cancer when it is advanced or has spread or come back, and cannot be treated with surgery. Zirabev can be used unless the cancer

2019 European Medicines Agency - EPARs

76. Atezolizumab (non-small cell lung cancer) – Addendum to Commission A17-50

OAK and POPLAR. Both studies investigated the comparison of atezolizumab versus docetaxel in adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with disease progression during or after platinum-based chemotherapy for advanced disease. Both studies were therefore relevant for research question 1 of dossier assessment A17-50 on atezolizumab (patients for whom treatment with docetaxel, pemetrexed or nivolumab is indicated [1]). However, the data presented (...) Association for the Study of Lung Cancer; IC: immune cells; NSCLC: non-small cell lung cancer; PD-L1: programmed cell death ligand 1; TC: tumour cells; UICC: Union for International Cancer Control The G-BA decides on the added benefit. Addendum A18-09 Version 1.0 Atezolizumab – Addendum to Commission A17-50 23 February 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - 8 - 4 References 1. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Atezolizumab (nicht kleinzelliges

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

77. Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal)

Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) Dabr Dabrafenib with tr afenib with trametinib for treating ametinib for treating advanced metastatic BRAF V600E advanced metastatic BRAF V600E mutation-positiv mutation-positive non-small-cell lung e non-small-cell lung cancer (terminated appr cancer (terminated appraisal) aisal) T echnology appraisal guidance Published: 27 February 2019 nice.org.uk (...) /guidance/ta564 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Contents Contents Advice 3 Information 3 Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non- small-cell lung cancer (terminated appraisal) (TA564) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 3Advice Advice NICE is unable to make

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

78. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater Full Text available with Trip Pro

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater In the randomized, open-label, phase III KEYNOTE-024 study, pembrolizumab significantly improved progression-free survival and overall survival (OS) compared with platinum-based chemotherapy in patients with previously untreated advanced non-small-cell lung cancer (NSCLC) with a programmed death ligand 1 tumor proportion

2019 EvidenceUpdates

79. Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer. Full Text available with Trip Pro

Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer. 30667494 2019 02 19 2019 07 23 1538-3598 321 3 2019 01 22 JAMA JAMA Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer. 306-307 10.1001/jama.2018.18085 Denis Fabrice F Institut Inter-régional de Cancérologie Jean Bernard, Le Mans, France. Basch Ethan E Lineberger Comprehensive Cancer Center, University of North (...) Internet Kaplan-Meier Estimate Lung Neoplasms diagnosis diagnostic imaging mortality Neoplasm Recurrence, Local diagnosis Population Surveillance methods Self Report Symptom Assessment methods 2019 1 23 6 0 2019 1 23 6 0 2019 3 21 6 0 ppublish 30667494 2721170 10.1001/jama.2018.18085 PMC6439676

2019 JAMA Controlled trial quality: uncertain

80. Crizotinib (Alunbrig) - for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)

Crizotinib (Alunbrig) - for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization

2019 Health Canada - Drug and Health Product Register